Ionic Liquid Platform For Oral Biologics & Peptides

  • Ionic liquids (ILs) hold the promise of transforming injectable biologics and peptides into oral therapies
  • IL platform originally designed in Harvard University labs to overcome known barriers for oral delivery
  • Proprietary compositions developed from ingredients with a history of human exposure to form New Chemical Entities (NCEs)
  • i2o has developed a 150+ proprietary ionic liquid library with extensive IP and expertise

MEDICITM Drug Delivery System For Twice Yearly Biologics & Peptides

  • Small subcutaneous osmotic implants designed to deliver twice-yearly continuous maintenance dosing
  • Proprietary formulations for keeping APIs stable at body temperatures for multi-year periods of time
  • Short in-office procedures designed for optimal customer experience and normal office flow

Our Proprietary Cardiometabolic Medicines

  • ITCA 650 (exenatide twice-yearly MediciTM implants)
  • Additional long-acting GLP-1 receptor agonists (LA GLP-1 RAs)
  • Several long acting gut peptides to be combined with LA GLP-1 RAs